|
|
Tony Hunter
J Clin Invest. 2007;
117(8):2036
doi:10.1172/JCI31691
Abstract |
Full text
| PDF
T
he scientists of today have become accustomed to the extremely rapid pace of progress in the biomedical sciences spurred on by the discovery of recombinant DNA and the advent of automated DNA sequencing and PCR, with progress usually being measured in months or years at most. What is often forgotten, however, are the many prior advances that were needed to reach our present state of knowledge. Here I illustrate this by discussing the scientific discoveries made over the course of the past century and a half that ultimately led to the recent successful development of drugs, particularly imatinib mesylate, to treat chronic myelogenous leukemia.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(18)
| Title and authors |
Publication |
Year |
Handbook of Statistical Systems Biology
William S. Hlavacek
|
Handbook of Statistical Systems Biology
|
2011 |
AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma
T. Namiki, A. Tanemura, J. C. Valencia, S. G. Coelho, T. Passeron, M. Kawaguchi, W. D. Vieira, M. Ishikawa, W. Nishijima, T. Izumo, Y. Kaneko, I. Katayama, Y. Yamaguchi, L. Yin, E. C. Polley, H. Liu, Y. Kawakami, Y. Eishi, E. Takahashi, H. Yokozeki, V. J. Hearing
|
Proceedings of the National Academy of Sciences
|
2011 |
From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management
M Sudol
|
Oncogene
|
2011 |
Hypersensitivity Reaction to a Mosquito Bite in a Patient with Chronic Myeloid Leukemia
Uri P. Dior, Shaden Salameh, Yonatan Gershinsky, Ruth Stalnikowicz
|
Case Reports in Emergency Medicine
|
2011 |
Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside
Jacopo Olivieri, Sabrina Coluzzi, Imma Attolico, Attilio Olivieri
|
ScientificWorldJournal
|
2011 |
Dissecting phosphorylation networks: lessons learned from yeast
Janine Mok, Xiaowei Zhu, Michael Snyder
|
Expert Rev Proteomics
|
2011 |
Host-pathogen interactions: Manipulation of kinase signaling by bacterial pathogens
K. Orth, A. M. Krachler, A. R. Woolery
|
The Journal of Cell Biology
|
2011 |
Targeting non-malignant disorders with tyrosine kinase inhibitors
Friedrich Grimminger, Ralph T. Schermuly, Hossein A. Ghofrani
|
Nat Rev Drug Discov
|
2010 |
ChimerDB 2.0--a knowledgebase for fusion genes updated.
Pora Kim, Suhyeon Yoon, Namshin Kim, Sanghyun Lee, Minjeong Ko, Haeseung Lee, Hyunjung Kang, Jaesang Kim, Sanghyuk Lee
|
Nucleic Acids Research
|
2010 |
Cytogenetics and genetics of human cancer: methods and accomplishments
Avery A. Sandberg, Aurelia M. Meloni-Ehrig
|
Cancer Genetics and Cytogenetics
|
2010 |
|